MET amplification
|
CRC
|
MET amplification
|
CRC
|
cabozantinib tablet Sensitive: D – Preclinical
J Pediatr Hematol Oncol - 2 weeks (NewD)
|
cabozantinib tablet Sensitive: D – Preclinical
J Pediatr Hematol Oncol - 2 weeks - (New D)
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
tepotinib Sensitive: A2 - Guideline
|
tepotinib Sensitive: A2 - Guideline
|
MET amplification
|
RCC
|
MET amplification
|
RCC
|
savolitinib Sensitive: A2 - Guideline
|
savolitinib Sensitive: A2 - Guideline
|
MET amplification
|
Gastroesophageal Junction Adenocarcinoma
|
MET amplification
|
Gastroesophageal Junction Adenocarcinoma
|
AMG 102 Resistant: B - Late Trials
|
AMG 102 Resistant: B - Late Trials
|
MET amplification
|
Gastric Adenocarcinoma
|
MET amplification
|
Gastric Adenocarcinoma
|
AMG 102 Resistant: B - Late Trials
|
AMG 102 Resistant: B - Late Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria
|
bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
SCC244 Sensitive: C2 – Inclusion Criteria
|
SCC244 Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria
|
gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
Gastric Cancer
|
MET amplification
|
Gastric Cancer
|
TPX-0022 Sensitive: C2 – Inclusion Criteria
|
TPX-0022 Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria
|
osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
Lung Cancer
|
MET amplification
|
Lung Cancer
|
tepotinib Sensitive: C2 – Inclusion Criteria
|
tepotinib Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
APL-101 Sensitive: C2 – Inclusion Criteria
|
APL-101 Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
crizotinib + osimertinib Sensitive: C2 – Inclusion Criteria
|
crizotinib + osimertinib Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
capmatinib Sensitive: C2 – Inclusion Criteria
|
capmatinib Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
Gastric Cancer
|
MET amplification
|
Gastric Cancer
|
savolitinib Sensitive: C2 – Inclusion Criteria
|
savolitinib Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
RCC
|
MET amplification
|
RCC
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
Head and Neck Cancer
|
MET amplification
|
Head and Neck Cancer
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
Gastric Adenocarcinoma
|
MET amplification
|
Gastric Adenocarcinoma
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
U3-1402 Sensitive: C3 – Early Trials
|
U3-1402 Sensitive: C3 – Early Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
MET amplification
|
Gallbladder Cancer
|
MET amplification
|
Gallbladder Cancer
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
c-MET inhibitor Sensitive: C3 – Early Trials
|
c-MET inhibitor Sensitive: C3 – Early Trials
|
MET amplification
|
CRC
|
MET amplification
|
CRC
|
TPX-0022 Sensitive: C3 – Early Trials
|
TPX-0022 Sensitive: C3 – Early Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
gefitinib + savolitinib Sensitive: C3 – Early Trials
|
gefitinib + savolitinib Sensitive: C3 – Early Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
MET amplification
|
Solid Tumor
|
MET amplification
|
Solid Tumor
|
TQ-B3101 Sensitive: C3 – Early Trials
|
TQ-B3101 Sensitive: C3 – Early Trials
|
MET amplification
|
Gastric Cancer
|
MET amplification
|
Gastric Cancer
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
MET amplification
|
LUAD
|
MET amplification
|
LUAD
|
crizotinib + osimertinib Sensitive: C3 – Early Trials
|
crizotinib + osimertinib Sensitive: C3 – Early Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
gefitinib Resistant: C3 – Early Trials
|
gefitinib Resistant: C3 – Early Trials
|
MET amplification
|
Gastroesophageal Cancer
|
MET amplification
|
Gastroesophageal Cancer
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
MET amplification
|
LUAD
|
MET amplification
|
LUAD
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
MET amplification
|
CRC
|
MET amplification
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
MET amplification
|
CRC
|
MET amplification
|
CRC
|
panitumumab Resistant: C3 – Early Trials
|
panitumumab Resistant: C3 – Early Trials
|
MET amplification
|
HER2 Positive Breast Cancer
|
MET amplification
|
HER2 Positive Breast Cancer
|
trastuzumab Resistant: C3 – Early Trials
|
trastuzumab Resistant: C3 – Early Trials
|
MET amplification
|
LUAD
|
MET amplification
|
LUAD
|
erlotinib + gefitinib + icotinib Sensitive: C3 – Early Trials
|
erlotinib + gefitinib + icotinib Sensitive: C3 – Early Trials
|
MET amplification
|
Gastroesophageal Cancer
|
MET amplification
|
Gastroesophageal Cancer
|
afatinib Resistant: C3 – Early Trials
|
afatinib Resistant: C3 – Early Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
osimertinib Resistant: C3 – Early Trials
|
osimertinib Resistant: C3 – Early Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
lorlatinib Resistant: C3 – Early Trials
|
lorlatinib Resistant: C3 – Early Trials
|
MET amplification
|
Sarcoma
|
MET amplification
|
Sarcoma
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
gefitinib + tepotinib Sensitive: C3 – Early Trials
|
gefitinib + tepotinib Sensitive: C3 – Early Trials
|
MET amplification
|
Pancreatic Cancer
|
MET amplification
|
Pancreatic Cancer
|
cetuximab Resistant: C4 – Case Studies
|
cetuximab Resistant: C4 – Case Studies
|
MET amplification
|
Biliary Tract Cancer
|
MET amplification
|
Biliary Tract Cancer
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
MET amplification
|
Cholangiocarcinoma
|
MET amplification
|
Cholangiocarcinoma
|
c-MET inhibitor Sensitive: C4 – Case Studies
|
c-MET inhibitor Sensitive: C4 – Case Studies
|
MET amplification
|
GBM
|
MET amplification
|
GBM
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
MET amplification
|
GBM
|
MET amplification
|
GBM
|
cediranib Resistant: C4 – Case Studies
|
cediranib Resistant: C4 – Case Studies
|
MET amplification
|
Gastric Adenocarcinoma
|
MET amplification
|
Gastric Adenocarcinoma
|
RG3638 Sensitive: C4 – Case Studies
|
RG3638 Sensitive: C4 – Case Studies
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
selpercatinib Resistant: C4 – Case Studies
|
selpercatinib Resistant: C4 – Case Studies
|
MET amplification
|
HCC
|
MET amplification
|
HCC
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
MET amplification
|
Cholangiocarcinoma
|
MET amplification
|
Cholangiocarcinoma
|
capmatinib Sensitive: C4 – Case Studies
|
capmatinib Sensitive: C4 – Case Studies
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
osimertinib + HQP8361 Sensitive: D – Preclinical
|
osimertinib + HQP8361 Sensitive: D – Preclinical
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
HQP8361 Sensitive: D – Preclinical
|
HQP8361 Sensitive: D – Preclinical
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
CKD-702 Sensitive: D – Preclinical
|
CKD-702 Sensitive: D – Preclinical
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
afatinib Resistant: D – Preclinical
|
afatinib Resistant: D – Preclinical
|
MET amplification
|
Gastric Cancer
|
MET amplification
|
Gastric Cancer
|
JNJ-38877605 Sensitive: D – Preclinical
|
JNJ-38877605 Sensitive: D – Preclinical
|
MET amplification
|
Gastric Cancer
|
MET amplification
|
Gastric Cancer
|
SGX523 Sensitive: D – Preclinical
|
SGX523 Sensitive: D – Preclinical
|
MET amplification
|
Gastroesophageal Cancer
|
MET amplification
|
Gastroesophageal Cancer
|
savolitinib + capmatinib Sensitive: D – Preclinical
|
savolitinib + capmatinib Sensitive: D – Preclinical
|
MET amplification
|
NSCLC
|
MET amplification
|
NSCLC
|
GB263T Sensitive: D – Preclinical
|
GB263T Sensitive: D – Preclinical
|